Approach to Hives in a Young Adult

Initial Assessment and Treatment

The American College of Physicians recommends starting with a second-generation non-sedating H1 antihistamine at standard dosing, and if symptoms persist after 2-4 weeks, increase the dose up to 4 times the standard dose before considering additional therapies 1, 2
Patients with chronic spontaneous urticaria unresponsive to high-dose antihistamines may be treated with omalizumab 300 mg subcutaneously every 4 weeks, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 2

The American Academy of Allergy, Asthma, and Immunology suggests offering the patient a choice of at least two different non-sedating antihistamines, as individual responses and tolerance vary significantly 1, 2
Cetirizine has the shortest time to maximum concentration, advantageous for rapid relief, according to the American College of Clinical Pharmacy 3

The American College of Allergy, Asthma, and Immunology recommends allowing up to 6 months for response to omalizumab before declaring treatment failure 1, 2
At least 30% of patients have insufficient response to omalizumab, particularly those with IgG-mediated autoimmune urticaria, as noted by the European Academy of Allergy and Clinical Immunology 1, 2

The British Society for Allergy and Clinical Immunology suggests that cyclosporine is effective in approximately 54-73% of patients, particularly those with autoimmune chronic spontaneous urticaria who don't respond to omalizumab 1, 2, 3

The American Academy of Dermatology recommends identifying and minimizing aggravating factors such as overheating, stress, and alcohol 1, 2, 3

The American College of Physicians advises restricting oral corticosteroids to short courses (3-10 days) for severe acute exacerbations only, due to cumulative toxicity, as recommended by the Mayo Clinic Proceedings 2, 3, 4

The American Academy of Allergy, Asthma, and Immunology counsels patients that approximately 50% with chronic urticaria presenting with wheals alone will be clear by 6 months, though those with both wheals and angioedema have a poorer outlook with over 50% still having active disease after 5 years 2

The National Kidney Foundation recommends avoiding acrivastine in moderate renal impairment, and halving the dose of cetirizine, levocetirizine, and hydroxyzine in moderate renal impairment 2
The American Association for the Study of Liver Diseases advises avoiding mizolastine in significant hepatic impairment, and avoiding hydroxyzine in severe liver disease 1, 2